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Additive Value of Preprocedural Computed
Tomography Planning Versus Stand-Alone
Transesophageal Echocardiogram Guidance
to Left Atrial Appendage Occlusion:
Comparison of Real-World Practice
Chak-yu So , MD, MBChB; Guson Kang, MD; Pedro A. Villablanca, MD, MSc; Abel Ignatius , MD;
Saleha Asghar , MD; Dilshan Dhillon , MD; James C. Lee , MD; Arfaat Khan, MD; Gurjit Singh , MD;
Tiberio M. Frisoli, MD; Brian P. O’Neill, MD; Marvin H. Eng , MD; Thomas Song , MD; Milan Pantelic, MD;
William W. O’Neill, MD; Dee Dee Wang , MD
BACKGROUND: Transesophageal echocardiogram is currently the standard preprocedural imaging for left atrial appendage
occlusion. This study aimed to assess the additive value of preprocedural computed tomography (CT) planning versus stand-
alone transesophageal echocardiogram imaging guidance to left atrial appendage occlusion.
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METHODS AND RESULTS: We retrospectively reviewed 485 Watchman implantations at a single center to compare the outcomes
of using additional CT preprocedural planning (n=328, 67.6%) versus stand-alone transesophageal echocardiogram guidance (n=157, 32.4%) for left atrial appendage occlusion. The primary end point was the rate of successful device implantation without major peri-device leak (>5 mm). Secondary end points included major adverse events, total procedural time,
delivery sheath and devices used, risk of major peri-device leak and device-related thrombus at follow-up imaging. A single/
anterior-curve delivery sheath was used more commonly in those who underwent CT imaging (35.9% versus 18.8%; P<0.001).
Additional preprocedural CT planning was associated with a significantly higher successful device implantation rate (98.5%
versus 94.9%; P=0.02), a shorter procedural time (median, 45.5 minutes versus 51.0 minutes; P=0.03) and a less frequent
change of device size (5.6% versus 12.1%; P=0.01), particularly device upsize (4% versus 9.4%; P=0.02). However, there was
no significant difference in the risk of major adverse events (2.1% versus 1.9%; P=0.87). Only 1 significant peri-device leak
(0.2%) and 5 device-related thrombi were detected in follow-up (1.2%) with no intergroup difference.
CONCLUSIONS: Additional preprocedural planning using CT in Watchman implantation was associated with a higher successful
device implantation rate, a shorter total procedural time, and a less frequent change of device sizes.
Key Words: atrial fibrillation ■ computed tomography ■ left atrial appendage occlusion ■ three-dimensional printing ■ transesophageal
echocardiography

L

eft atrial appendage (LAA) occlusion (LAAO) is
a nonpharmacologic therapy for stroke prophylaxis in selected patients with nonvalvular atrial

fibrillation (AF).1 The anatomy of LAA is highly variable, and hence preprocedural imaging is important for procedural planning and device selection.2
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Added Value of CT for LAAO

CLINICAL PERSPECTIVE
What Is New?

• Additional preprocedural planning in Watchman
implantation using computed tomography was
associated with a significantly higher rate of
successful device implantation, a shorter total
procedural time, and a less frequent need to
change device sizes.

What Are the Clinical Implications?

• A large-scale randomized controlled trial comparing the 2 imaging modalities in different left
atrial appendage occlusion devices is needed.
• A streamlined computed tomography planning protocol without a 3-dimensional–printed
model should be developed to reduce cost and
improve reproducibility.

Nonstandard Abbreviations and Acronyms
LAA
TEE

left atrial appendage
transesophageal echocardiogram
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Two-
dimensional transesophageal echocardiogram
(TEE) is currently the gold standard imaging modality
for both pre-and intraprocedural guidance.3 Previous
studies found that 3-dimensional cardiac computed
tomography (CT) reported consistently larger LAA dimensions than TEE,4–6 and a number of small comparative studies showed that preprocedural planning
using 3-dimensional CT was associated with more accurate device selection and improved procedural efficiency.7–9 However, it was uncertain whether additional
preprocedural planning using 3-dimensional CT would
impact on the LAAO procedural success, procedural
safety, and subsequent occlusion outcomes. This
study aimed to assess the additive value of preprocedural CT planning versus stand-alone TEE imaging
guidance to LAAO.

procedure to assess the LAA anatomy. Patients with presence of a LAA thrombus or who were anatomically not
suitable for the Watchman device according to the device
instructions for use were excluded.10 Preprocedural planning was performed using either CT or TEE according to
the operator’s preference. Preprocedural CT was obtained
at least 72 hours before the actual procedure to reduce
risk of contrast nephropathy, whereas preprocedural TEE
was performed days/weeks before or on the same day
as the actual procedure. Patients were then divided into
2 groups, using additional CT for preprocedural planning
versus stand-alone TEE-guided LAAO, to compare the
outcomes of the Watchman implantation. The study was
approved by the Henry Ford Hospital institutional review
board, and informed consent was waived for this retrospective analysis.

Preprocedural CT Protocol
The CT imaging acquisition and postprocessing protocol at our institution were previously described.6 In
short, contrast-enhanced, cardiac CT angiographic
acquisition was obtained using GE Discovery CT750
(GE Healthcare, Waukesha, WI) and image postprocessing was performed using Vitrea (Vital Images,
Minnetonka, MN) and Mimics (Materialise, Leuven,
Belgium). LAA dimensions were measured at the late
ventricular systolic phase that corresponds with the
maximal end-diastolic filling for the LAA. Maximal and
minimal diameters of the LAA landing zone, and the
length/depth of the LAA from the landing zone to the
distal LAA tip were measured (Figure). Device size
was determined by the widest diameter of the landing zone measured by CT imaging and selection according to the Watchman instructions for use. Optimal
C-arm deployment angle, depth of deployment, and
catheter tip positioning to optimize device implant
coaxiality to the LAA were also determined by CT
for procedural guidance. In addition, 3-dimensional
prints of patient’s specific left atrial and LAA anatomy
were generated to assist in bench-test selection of
catheter curvature for device implantation. However,
device size testing or procedure simulation was not
performed.

Intraprocedural Imaging

METHODS
The authors declare that all supporting data are available within the article.

Study Design
We retrospectively reviewed all LAAO using the Watchman
device (Boston Scientific, Marlborough, MA) performed at
a single center from May 2015 to December 2019. All patients underwent preprocedural imaging before the actual

All Watchman implantations were performed under real-
time TEE guidance. Two-dimensional and 3-dimensional
LAA measurements were obtained after confirming mean LA pressure >10 mm Hg. For the additive
CT group, the initial device size and choice of delivery
sheath followed the preprocedural plan unless difficulty occurred intraprocedurally because of challenging
transseptal access and ability to achieve device coaxiality. A CT-derived LAA angiogram at the deployment projection was printed out as a road map. Intraprocedural
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LAA angiogram was obtained with reference to the road
map before device implantation. On the other hand, in
the stand-alone TEE group, the choice of device size
relied on the intraprocedural TEE measurements, and
the choice of delivery sheath was decided by individual
implanter after transseptal access and LAA angiogram.

End Points
The primary end point for the study was the rate of successful device implantation without major peri-device
leak (>5 mm). Secondary end points included major
adverse events, total procedural time (defined by start
of vascular access to vascular closure, ie, skin-to-skin
time), radiation dose, total contrast used, number and
types of delivery sheath used, number of devices used,
number of partial recaptures, and risk of significant
peri-device leak (>5 mm) and device-related thrombus at follow-up imaging (45 days after implantation).
Major adverse events included device embolization,
procedural-
related myocardial infarction, procedural
stroke, new pericardial effusion requiring intervention,
surgical conversion, and procedural death.

Statistical Analysis
SPSS version 24 (IBM, Armonk, NY) and Microsoft
Excel 365 (Microsoft Corp., Redmond, WA) were used
for all statistical analyses. Categorical variables were

summarized as percentages. Normally distributed continuous data were expressed as mean±SD and skewed
data as median (interquartile range). Unpaired Student
t test was used to compare means of 2 independent
samples and independent samples median test was
used to compare medians. Differences between groups
were assessed using the chi-square test for independence. In case the frequency of an observation was <5
in the contingency table, Fisher’s exact test was used
instead. A multiple logistic regression test was used to
identify independent predictors of successful device
implantation, change of device size, and device upsize.
Statistical significance was defined as P<0.05.

RESULTS
From May 2015 to December 2019, a total of 485
LAAOs were performed using the Watchman device,
including 328 (67.6%) cases who underwent additional
CT for preprocedural planning and 157 (32.4%) cases
using stand-alone TEE for guidance. The baseline patient characteristics were shown in Table 1. Patients in
the additive CT group had a significantly lower body
mass index (28.7±6.2 versus 30.9±6.8; P=0.001) and
higher HAS-
BLED score (3.2±1.0 versus 2.9±1.0;
P=0.006); otherwise, there were no significant difference in their baseline clinical profiles, including
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Table 1. Baseline Patient Characteristics
Overall (n=485)

Additive CT (n=328)

Stand-Alone TEE
(n=157)

P Value

Age

77.5±8.5

77.5±8.7

77.4±8.2

0.93

Sex, male

265 (54.6)

180 (54.9)

85 (54.1)

0.88

BMI, kg/m2

29.4±6.4

28.7±6.2

30.9±6.8

0.001

CHADS2-VASc Score

4.5±1.5

4.5±1.5

4.5±1.3

0.85

HAS-BLED score

3.1±1.0

3.2±1.0

2.9±1.0

0.006

History of CHF

232 (47.8)

165 (50.3)

67 (42.7)

0.12

History of hypertension

438 (90.3)

296 (90.2)

142 (90.4)

0.94

History of DM

198 (40.8)

125 (38.1)

73 (46.5)

0.08

History of Stroke/TIA

179 (36.9)

130 (39.6)

49 (31.2)

0.07

History of prior bleeding

404 (83.3)

272 (82.9)

132 (84.1)

0.75

68 (14)

45 (13.7)

23 (14.6)

0.78

231 (45.9)

150 (45.7)

81 (51.6)

0.23

56 (11.5)

40 (12.2)

16 (10.2)

0.52

55.9±10.7

55.6±11.2

56.4±9.5

0.42

20 (4.1)

13 (4.0)

7 (4.5)

0.80

Baseline creatinine, mg/dL

1.1 (0.5)

1.085 (0.50)

1.1 (0.58)

0.70

Maximum ostium diameter
(intraprocedural TEE), mm†

22.4±3.9

22.4±3.7

22.4±3.6

0.96

History of ICH
History of gastrointestinal bleed
History of renal impairment*
LVEF, %
Concomitant procedures

Data were presented as mean ±SD or median (interquartile range) or n (%). BMI indicates body mass index; CHF, congestive heart failure; CT, computed
tomography; DM, diabetes mellitus; ICH, intracranial hemorrhage; LVEF, left ventricular ejection fraction; TEE, transesophageal echocardiogram; and TIA,
transient ischemic attack.
*Renal dialysis, renal transplant, creatinine >2.26 mg/dL or >200 µmol/L.
†
For those with successful Watchman implantation.
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Table 2. Left Atrial Appendage Sizing Analysis by CT Versus TEE for the Same Patient
CT

TEE

Mean Difference

P Value

Maximum ostium diameter, mm

25.2 ± 3.7

22.4 ± 3.8

+2.8 (+2.2 to +3.4)

<0.001

Minimum ostium diameter, mm

20.3 ± 4.0

17.0 ± 3.3

+3.4 (+2.8 to +4.0)

<0.001

Maximum depth, mm

29.7 ± 6.8

29.2 ± 5.4

+ 0.5 (−0.4 to +1.5)

0.28

Data are presented as mean±SD or mean difference (95% CI). CT indicates computed tomography; and TEE, transesophageal echocardiogram.

the baseline creatinine level. The maximum landing
zone diameters measured by intraprocedural TEE between the 2 groups were similar (22.4±3.7 mm versus
22.4±3.6 mm; P=0.96). In the additive CT group, the
maximal landing zone diameter measured by CT was
2.8±2.4 mm larger than that measured by intraprocedural 2-dimensional TEE, which was consistent with
previously published data4–6 (Table 2).

also less common to change device size after initial
deployment in the additive CT group than the stand-
alone TEE group (5.6% versus 12.1%; P=0.01), with
significantly more device upsizing in the stand-alone
TEE group (4% versus 9.4%; P=0.02). With multiple logistic regression analysis, it was found that additional
CT had a significant association with successful device
implantation (odds ratio [OR], 3.63; 95% CI, 1.06–12.5;
P=0.041), stand-alone TEE had a significant association with change of device size (OR, 2.34; 95% CI,
1.17–4.62; P=0.016), stand-alone TEE (OR, 2.51; 95%
CI, 1.14–5.52; P=0.022), and history of hypertension
(OR, 0.33; 95% CI, 0.12–0.87; P=0.025) had significant
associations with device upsize.

Procedural Features and Outcomes

Downloaded from http://ahajournals.org by on September 29, 2021

Patients’ who had additive CT for preprocedural planning had a significantly higher rate of successful device implantation with <5 mm peri-device leak than
using stand-alone TEE (98.5% versus 94.9%, P=0.02;
Table 3). There was no significant difference in the
risk of major adverse events between the 2 groups
(2.1% versus 1.9%; P=0.87). Total procedural time was
shorter in the additive CT group than the stand-alone
TEE group (median, 45.5 minutes [36.75–59.00] versus
51.0 minutes [39.00–66.50]; P=0.03; Table 4). The total
contrast used was significantly more in the additive CT
group (59.2±34.5 mL versus 51.5±35.9 mL; P=0.05).
The additive CT group used more anterior or single
curve delivery sheath (35.9% versus 18.8%; P<0.001)
than the stand-alone TEE group (single curve, 11.1%
versus 7.7%; double curve, 64.1% versus 81.2%; anterior curve, 24.8% versus 16.8%; P<0.001). Moreover,
the devices used between the 2 groups were significantly different (Table 4), with fewer 21-mm devices
(7.4% versus 12.8%) and more 33 mm devices (18.6%
versus 10.1%) used in the additive CT group. It was

Follow-Up Clinical and Imaging Outcomes
The overall follow-up imaging rate was high, with no
significant difference between the 2 groups (overall,
93.2%; additive CT group 93.8% versus stand-alone
TEE group, 91.9%; P=0.46; Table 5). A majority of patients in the additive CT group (68.4%) received CT
as follow-up imaging, whereas the stand-alone TEE
group received TEE (81.9%) instead. There was only
1 significant peri-
device leak (>5 mm; 0.2%) and 5
device-related thrombi detected (1.2%), with no difference between the 2 groups.

DISCUSSION
The main finding of our study was that additional preprocedural planning using CT when compared with

Table 3. Procedural Outcomes and Complications

Successful device implantation
Major adverse events
Device embolization
Procedural related MI
Procedural stroke
New pericardial effusion
Pericardial effusion requiring
intervention
Surgical conversion
Peri-procedural death

Overall (n=485)

Additive CT
(n=328)

Stand-Alone TEE
(n=157)

Odds Ratio (95% CI)

P Value

472 (97.3)

323 (98.5)

149 (94.9)

3.45 (1.11–11.1)

0.02

10 (2.1)

7 (2.1)

3 (1.9)

0.87

0

0

0

0.99

0

0

0

0.99

1 (0.2)

1 (0.3)

0

0.99

7 (1.4)

5 (1.5)

2 (1.3)

0.99

4 (0.8)

3 (0.9)

1 (0.6)

0.99

0

0

0

0.99

2 (0.4)

1 (0.3)

1 (0.6)

0.54

Data are presented as n (%). CT indicates computed tomography; MI, myocardial infarction; and TEE, transesophageal echocardiogram.
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Procedural Characteristics of Successful Watchman Implantations
Overall (n=472)

Additive CT
(n=323)

Stand-Alone TEE
(n=149)

Difference

P Value

48 (37, 61)

45.5 (37, 59)

52.5 (39, 66)

–7.0

0.03

Total radiation dose, mGy

219 (126, 418)

239.0 (139, 427)

176 (90, 373)

+63

0.03

Total contrast used, mL

50.0 (30, 75)

50.0 (35, 76)

40.0 (20, 75)

+10

0.30

Total procedural time (skin to skin),
min

Odds radio (95% CI)
Delivery sheath used

<0.001

Single curve

39 (8.3)

36 (11.1)

3 (2.0)

Double curve

328 (69.5)

207 (64.1)

121 (81.2)

Anterior curve

105 (22.2)

80 (24.8)

25 (16.8)

Anterior or single curve

144 (30.5)

116 (35.9)

28 (18.8)

Number of delivery sheath used

1 (1, 1)

1 (1, 1)

1 (1, 1)

0.91

Change of delivery Sheath

23 (4.9)

16 (5.0)

7 (4.7)

0.99

Device implanted

0.02

21 mm

43 (9.1)

24 (7.4)

19 (12.8)

24 mm

112 (23.7)

84 (26.0)

28 (18.8)

27 mm

142 (30.1)

91 (28.2)

51 (34.2)

30 mm

100 (21.2)

64 (19.8)

36 (24.2)

33 mm

15 (10.1)

75 (15.9)

60 (18.6)

Number of device used

1 (1, 1)

1 (1, 1)

1 (1, 1)

Change of device size

36 (7.6)

18 (5.6)

18 (12.1)

2.3 (1.1–4.6)

0.02

27 (5.7)

13 (4)

14 (9.4)

2.4 (1.1–5.4)

0.031

Upsize
Downsize
Number of partial recapture
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Need of partial recapture

0.84

9 (1.9)

5 (1.5)

4 (2.7)

0.47

0 (0, 0)

0 (0, 0)

0 (0, 0)

0.99

112 (23.7)

77 (23.8)

35 (23.5)

0.79

Data are presented as median (25th percentile, 75th percentile) or n (%). CT indicates computed tomography; mGy, milligray; and TEE, transesophageal
echocardiogram.

stand-alone TEE in LAAO using the Watchman device
was associated with a higher rate of successful device implantation, a shorter total procedural time, and
a less frequent need to change device sizes. Besides,
the additive CT group also had significant differences
in the choice of delivery sheath used and the size of
device implanted compared with the stand-alone TEE
group.

New Gold Standard
CT has become the gold standard for device sizing in transcatheter aortic valve replacement. The
LAA has a more complex anatomy and existing data
consistently showed that the maximal LAA landing
zones measured by CT were significantly bigger than
that measured by TEE,4–6 and device sizing according to CT measurements was more accurate.7–9 Our

Table 5. Clinical and Imaging Follow-Up Outcomes of Successful Watchman Implantations at 45 Days
Overall (n=472)
45-d clinical follow-up

Additive CT
(n=323)

Stand-Alone TEE
(n=149)

Odds Ratio (95% CI)

P Value

440 (93.2)

137 (91.9)

303 (93.8)

51 (10.8)

16 (10.7)

35 (10.8)

CT

232 (49.2)

11 (7.4)

221 (68.4)

TEE

189 (40.0)

122 (81.9)

67 (20.7)

1 (0.2)

0

1 (0.3)

Any PDL

79 (18.8)

42 (31.3)

DRT

5 (1.2%)

1 (0.7%)

45-d imaging follow-up
No follow-up imaging

Significant PDL (>5 mm)

<0.001

0.32 (0.2–0.54)

37 (12.9)
4 (1.4%)

Data are presented as n (%). CT indicates computed tomography; DRT, device-related thrombus; PDL, peri-device leak; and TEE, transesophageal
echocardiogram.
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Aggregate data combined from PROTECT-AF, PREVAIL, CAP, CAP2, and the Post-FDA Approval Experience. CAP indicates continued access to PROTECT-AF; CAP2, continued access to PREVAIL; CT, computed
tomography; FDA, Food and Drug Administration; LAA, left atrial appendage; N/A, not available; NCDR, National Cardiovascular Data Registry; PREVAIL, Prospective Randomized Evaluation of the Watchman
LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy; PROTECT-AF, Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation; and TEE,
transesophageal echocardiogram.
*P value when compared with Henry Ford Additive CT cohort.
†
NCDR reported success rate among those with device deployed, device not attempted were excluded (7% of procedures were cancelled/aborted for multiple reasons).

1.39

0.07
0.24

1.02
1.9

0
0.2

1.4
1.9

0.7
0.6

4.3

0
Device embolization, %

0

0.9
Pericardial tamponade, %

0.6

N/A
1.38
1.4
1.4
1.5
1.6
1.3
Number of device used,
mean

1.3

N/A
50 (36–66)
55 (39–80)
46 (34–62)
52 (40–73)
51 (37–71)
46 (37–59)
Procedure time, min,
median (1st–3rd quartile)

51 (39–67)

38 158

98.3†
95.6
P=0.0125*

3822
579

94.8
P=0.0060*
94.4
P=0.0028*

566
269

95.1
P=0.0187*
90.9
P<0.001*

463
157

Implantation success, %

94.9
P=0.02*

328

98.5

Number of procedures

Post-FDA Approval
Registry
CAP-2
CAP
PREVAIL
PROTECT-AF
Henry Ford Stand-
Alone TEE Cohort
Henry Ford Additive
CT Cohort

Comparison of Procedural Outcomes With Other Major Clinical Studies or Registry
Table 6.
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study supported these findings and was the first to
show that additional CT preprocedural planning was
associated with a higher rate of successful device
implantation. In fact, the rate of successful device
implantation in our CT cohort was significantly higher
than that reported in published US studies, with a
numerically lower median procedural time (Table 6).
In line with previous studies, CT measurements yield
larger LAA dimensions and more accurate device
sizing than TEE, which resulted in less frequent need
to upsize the device, as illustrated by our study. In
addition, we believed that a more tailored choice of
delivery sheath and fluoroscopic coaxial deployment
projection obtained by preprocedural CT contributed
to the improved rate of successful device implantation
and procedural efficiency. Most operators preferentially used a double-curve delivery sheath and right
anterior oblique 20 to 30 caudal 20 to 30 projection
for device deployment. From our analysis by in vitro
testing in a patient-
specific 3-
dimensional–
printed
model, coaxial alignment with the LAA ostium was
better achieved by a single-curve or anterior-curve
delivery sheath in a substantial proportion of patients. As a result, >30% of the cases in the additive CT group used a single/anterior-curve delivery
sheath for device deployment with an overall 5%
delivery sheath change only. We also found that, as
in coplanar projection during valve deployment in
transcatheter aortic valve replacement, a CT-derived
individualized fluoroscopy projection angle that
aligns the LAA ostium further improved deployment
accuracy and occlusion result. Paradoxically, more
contrast was used in the patients with additional CT
preprocedural planning. We speculated that more
contrast was used to obtain a LAA angiogram similar
to the CT-derived road map, that is, more forceful or
repeated injections to fill the whole LAA, before device implantation. However, there was no significant
difference in the risk of major adverse events, as the
overall risk reported in our study was low (Table 6).11–
15
Whether additive CT would improve the safety of
Watchman implantation in lower volume or new implant sites remains to be proven. In addition, the overall risk of device-related thrombus was significantly
lower than that reported in recent series,16 whether
this was related to additive CT planning, implantation technique, or postimplantation antithrombotic
remained unclear. Finally, the adoption of additional
CT preprocedural planning±follow-up imaging modality could reduce the need to subject patients to
multiple TEE, and thus improve patient comfort, reduce the risk of esophageal injury, aspiration, and
sedation. On the other hand, contrast CT carries the
risk of contrast nephropathy. However, by excluding
patients with severe chronic kidney disease, spacing
out contrast exposure and adequate prehydration,
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Figure. Case example of Watchman implantation using computed tomography (CT) for preprocedural planning.
A, Left atrial appendage (LAA) landing zone dimensions measured by CT. B, The depth measured perpendicular to the LAA landing zone
and the optimal fluoroscopic deployment projection determined by CT. C, In vitro testing to select the curvature of the delivery sheath,
which achieved coaxiality to the LAA landing zone for optimal deployment. D, The landing zone size measured by intraprocedural
TEE, which was consistently smaller than that by preprocedural CT. E, LAA angiogram at predetermined fluoroscopic projection. F,
Postimplantation CT 3-dimensional reconstruction.

which is the standard for any kind of LAA imaging,
the risk of contrast nephropathy could be minimized.
Further analysis to compare the cost-effectiveness
of additional preprocedural CT planning versus
stand-alone TEE for LAAO, taking into account the
reduced lab time. In the era of COVID, TEE—being an
aerosol-generating procedure—can spread the virus
and pose a risk for echocardiographers, personnel,
and patients. Avoiding multiple TEEs during the pandemic could potentially reduce the risk of spreading
infection and reduce the use of personal protective
equipment and resources.

Future Directions
Although device size prediction accuracy by CT was
proven to be high, it was uncertain which parameter (maximal dimension, perimeter-
derived diameter, or area-derived diameter) performs the best. In
fact, the best parameter could be device specific,7
as in the case of transcatheter valves, and should
be determined next with increasing CT experience
in LAAO. Additionally, the combination of preprocedural CT and intraprocedural intracardiac echocardiography might further reduce the need of general
anesthesia, intubation, and multiple TEEs; improve

patient comfort; and make LAAO more minimalistic. Moreover, with an expected increase in the array
of LAAO devices available in the United States, the
value of CT in preprocedural planning for optimal device size and choice could not be overlooked. With
CT-based preprocedural planning, digital simulation,
and in vitro simulation in 3-dimensional–printed models, LAAO could be more personalized and become
safer and more efficient.

Study Limitations
First, this was a single-center retrospective study without randomization. Choice of additive CT versus stand-
alone TEE for preprocedural planning could be biased
by the individual operator’s preference. LAAO outcome
could be affected by the individual operator’s experience, which was not adjusted for in our study. Second,
patients screened as not eligible for the Watchman device were not available for analysis, and hence whether
additional preprocedural CT screened out more unfavorable LAA anatomy for the Watchman device than
stand-alone TEE remained uncertain. Third, in our additive CT cohort, a 3-dimensional–printed left atrium
and LAA model was generated for a majority of patients for bench testing of delivery sheath alignment.
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This approach involved extra resources and expertise
and might not be feasible in other sites. A completely
CT-based approach to determine the optimal choice
of delivery sheath is under validation, and hopefully to
simplify our approach and increase the reproducibility. Finally, only the Watchman device was used in our
study, and it was uncertain whether the result could be
generalized to other LAAO devices.

CONCLUSIONS
Additional preprocedural planning using CT when
compared with stand-alone TEE in LAAO using the
Watchman device was associated with a higher rate of
successful device implantation, a shorter total procedural time, and a less frequent need to change device
sizes.
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